

### Test Description

The MolQ *BRCA* Germline mutation test helps assess your risk of developing cancer by detecting a potentially harmful change (mutation) in *BRCA1* and *BRCA2* genes.

### Patient Demographic

**Name:** Ms Vidhi Garg  
**Sex:** Female  
**Date of Birth/Age:** 32 years  
**Disease:** Asymptomatic

### Clinician

**Clinician Name:** Dr Amit Verma  
**Medical Facility:** Dr AV Institute of Personalized Therapy and Cancer Research (IPTCR)  
**Pathologist:** Not Provided

### Specimen

**Booking ID:** 012207300085  
**Site:** NA  
**Sample Type:** Blood  
**Date of Collection:** 30-07-2022  
**Date of Booking:** 30-07-2022

## CLINICAL SYNOPSIS

The index patient, Dr. Aditi Srivastava, is an operated case of grade III, ER/Her2 Neu negative, PR positive, metastatic invasive ductal carcinoma left breast, diagnosed in September 2021. She has previously been operated for stage IIIc high grade serous carcinoma bilateral ovaries in 2017. She has a family history of breast cancer with her maternal uncle, maternal aunt, maternal cousin and younger sister affected. Dr. Aditi Srivastava was found to harbor a heterozygous variant, **c.2806\_2809del** in the *BRCA2* gene. Daughter of index patient is being evaluated for the same variant.

## RESULTS

**Variant is confirmed to be absent by Sanger sequencing.**

Gene (Transcript) #	Location	Variant	Relationship to Index Patient	Clinical condition of family member	Variation reported in family member*
<i>BRCA2</i> (ENST00000380152.8) <sup>1</sup>	Exon 11	chr13:g.32337161_32337164del; 7164del (HET); c.2806_2809del; (p.Ala938ProfsTer21)	Daughter	Asymptomatic	Absent

\*The exon number and nucleotide numbers will differ based on the reference file chosen and the database used.

## CLINICAL CORRELATION AND VARIANT INTERPRETATION


**Variant description:** A heterozygous 4 base pair deletion in exon 11 of the *BRCA2* gene (**chr13:g.32337161\_32337164del; c.2806\_2809del**) that results in a frameshift and premature truncation of the protein 21 amino acids downstream to codon 938 (**p.Ala938ProfsTer21**) was detected in the index patient (Sample ID: 7614893; Report Dated: 14th July 2022) by NGS and was further validated by Sanger sequencing (Figure 1A).

The same pathogenic variant is not detected in the asymptomatic daughter of the index patient, Ms Vidhi Garg (Figure 1B).

The variant detected in the test and its significance needs to be carefully correlated with the clinical indications of the index patient.

## RECOMMENDATION

Genetic counselling is recommended to interpret the significance of the results.



**Jatinder Kaur, PhD**  
Head, Molecular Biology & Genomics



**Dr. Gulshan Yadav, MD**  
Head, Pathology

**APPENDIX 1: TEST METHODOLOGY**

**Method**

**Targeted gene Sanger sequencing:** Exon 11 of the *BRCA2* gene was PCR-amplified, and the product was sequenced using Sanger sequencing. In case of mosaicism in leucocytes, the detection limits of Sanger sequencing for presence of variant are ~20%. The sequence was aligned to available reference sequence ENST00000380152.8<sup>1</sup> to detect variant using variant analysis software programs. Variant classification follows the tenets of American College of Medical Genetics (ACMG) guidelines<sup>2</sup>.

**DISCLAIMER**


About 0.44% of total cases are susceptible to allele dropout/dropin phenomenon, which can lead to misdiagnosis<sup>3</sup>.

**REFERENCES**

1. ENSEMBL: <http://www.ensembl.org>.
2. Green R. C., et al., American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med.* 2013 Jul;15(7):565-74
3. Blais, Jonatan et al. Risk of Misdiagnosis Due to Allele Dropout and False-Positive PCR Artifacts in Molecular Diagnostics. *The Journal of Molecular Diagnostics*, Volume 17, Issue 5, 505 – 514.

**Figure 1: Sequence chromatogram and alignment to the reference sequence showing the variant in exon 11 of the *BRCA2* gene (chr13:g.32337161\_32337164del; c.2806\_2809del; p.Ala938ProfsTer21) detected in heterozygous condition in the index patient, Dr. Aditi Srivastava (A) and not detected in the daughter of the index patient, Ms. Vidhi Garg (B).**

**A. 7614893: The index patient (Dr. Aditi Srivastava)**



**B. 7652043: Daughter of the index patient (Ms. Vidhi Garg)**

BRCA2 e.11	ACCATGGTTTTATATGGAGACACAGGTGATAAAC AAGCAACCCAAGTGTCAATTAAAAAAGATTT
7652043_BRCA2 e.11_F	ACCATGGTTTTATATGGAGACACAGGTGATAAAC AAGCAACCCAAGTGTCAATTAAAAAAGATTT
8 fragment bases at consensus position 421	390   400   410   420   430   440   450 ACCATGGTTTTATATGGAGACACAGGTGATAAAC AAGCAACCCAAGTGTCAATTAAAAAAGATTT
chr13:g.32337161_32337164del;c.2806_2809del (p.Ala938ProfsTer21)	

